سعر اتوموكسابكس Atomoxapex‏ 25 مجم 30 كبسولة 2026

Atomoxetine 25 mg hard gelatin capsule, pack of 30 capsules (Multi-Apex).

• Hypersensitivity to atomoxetine or capsule constituents; use with or within 14 days of an MAOI; narrow-angle glaucoma; pheochromocytoma or history of it; severe cardiovascular disorders that could deteriorate with increased blood pressure or heart rate.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased risk of suicidal ideation in pediatric patients 6 years and older; monitor closely for suicidal thoughts, clinical worsening or unusual behaviour changes, especially early in therapy and after dose changes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Severe liver injury has been reported; discontinue in patients with jaundice or laboratory evidence of liver injury. Increases in blood pressure and heart rate, and serious cardiovascular events, may occur; assess cardiac status before treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• MAOIsContraindicated with MAOIs or within 14 days of stopping an MAOI.DailyMed (U.S. National Library of Medicine)
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine)Increase atomoxetine exposure; dose adjustment (slower titration, lower target) is recommended.DailyMed (U.S. National Library of Medicine)

• Available data in pregnant women are insufficient to establish a drug-associated risk; some animal reproduction studies showed adverse developmental outcomes. A pregnancy exposure registry exists.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; atomoxetine is present in animal milk. Weigh benefits of breastfeeding against maternal need and potential effects on the child.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Atomoxetine: Thought to act through selective inhibition of the presynaptic norepinephrine transporter; precise mechanism in ADHD unknown (US Strattera label).